BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 21562037)

  • 1. EGFR signaling regulates tumor cell migration in craniopharyngiomas.
    Hölsken A; Gebhardt M; Buchfelder M; Fahlbusch R; Blümcke I; Buslei R
    Clin Cancer Res; 2011 Jul; 17(13):4367-77. PubMed ID: 21562037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour cell migration in adamantinomatous craniopharyngiomas is promoted by activated Wnt-signalling.
    Hölsken A; Buchfelder M; Fahlbusch R; Blümcke I; Buslei R
    Acta Neuropathol; 2010 May; 119(5):631-9. PubMed ID: 20131060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and prognostic role of annexin A2 in adamantinomatous craniopharyngioma.
    Wang Y; Deng J; Guo G; Tong A; Peng X; Chen H; Xu J; Liu Y; You C; Zhou L
    J Neurooncol; 2017 Jan; 131(1):21-29. PubMed ID: 27640198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor in cultured human retinal pigment epithelial cells.
    Yan F; Hui YN; Li YJ; Guo CM; Meng H
    Ophthalmologica; 2007; 221(4):244-50. PubMed ID: 17579290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible linkage between specific histological structures and aberrant reactivation of the Wnt pathway in adamantinomatous craniopharyngioma.
    Kato K; Nakatani Y; Kanno H; Inayama Y; Ijiri R; Nagahara N; Miyake T; Tanaka M; Ito Y; Aida N; Tachibana K; Sekido K; Tanaka Y
    J Pathol; 2004 Jul; 203(3):814-21. PubMed ID: 15221941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles.
    Hölsken A; Sill M; Merkle J; Schweizer L; Buchfelder M; Flitsch J; Fahlbusch R; Metzler M; Kool M; Pfister SM; von Deimling A; Capper D; Jones DT; Buslei R
    Acta Neuropathol Commun; 2016 Feb; 4():20. PubMed ID: 26927026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormal beta-catenin expression in oral cancer with no gene mutation: correlation with expression of cyclin D1 and epidermal growth factor receptor, Ki-67 labeling index, and clinicopathological features.
    Odajima T; Sasaki Y; Tanaka N; Kato-Mori Y; Asanuma H; Ikeda T; Satoh M; Hiratsuka H; Tokino T; Sawada N
    Hum Pathol; 2005 Mar; 36(3):234-41. PubMed ID: 15791567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MAP kinase and beta-catenin signaling in HGF induced RPE migration.
    Liou GI; Matragoon S; Samuel S; Behzadian MA; Tsai NT; Gu X; Roon P; Hunt DM; Hunt RC; Caldwell RB; Marcus DM
    Mol Vis; 2002 Dec; 8():483-93. PubMed ID: 12500177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling.
    Conde E; Angulo B; Tang M; Morente M; Torres-Lanzas J; Lopez-Encuentra A; Lopez-Rios F; Sanchez-Cespedes M
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):710-7. PubMed ID: 16467080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
    Huang Y; Li X; Jiang J; Frank SJ
    Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biglycan regulates the expression of EGF receptors through EGF signaling pathways in human articular chondrocytes.
    Iacob S; Cs-Szabo G
    Connect Tissue Res; 2010 Oct; 51(5):347-58. PubMed ID: 20367117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells.
    Gan Y; Shi C; Inge L; Hibner M; Balducci J; Huang Y
    Oncogene; 2010 Sep; 29(35):4947-58. PubMed ID: 20562913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adamantinomatous craniopharyngiomas express tumor stem cell markers in cells with activated Wnt signaling: further evidence for the existence of a tumor stem cell niche?
    Hölsken A; Stache C; Schlaffer SM; Flitsch J; Fahlbusch R; Buchfelder M; Buslei R
    Pituitary; 2014 Dec; 17(6):546-56. PubMed ID: 24356780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of aberrant beta-catenin and impaired p63 in craniopharyngiomas.
    Cao J; Lin JP; Yang LX; Chen K; Huang ZS
    Br J Neurosurg; 2010 Jun; 24(3):249-56. PubMed ID: 20128632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations.
    Cai CQ; Peng Y; Buckley MT; Wei J; Chen F; Liebes L; Gerald WL; Pincus MR; Osman I; Lee P
    Oncogene; 2008 May; 27(22):3201-10. PubMed ID: 18193092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and tyrosine phosphorylation of E-cadherin, beta- and gamma-catenin, and epidermal growth factor receptor in cervical cancer cells.
    Moon HS; Choi EA; Park HY; Choi JY; Chung HW; Kim JI; Park WI
    Gynecol Oncol; 2001 Jun; 81(3):355-9. PubMed ID: 11371122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Target gene activation of the Wnt signaling pathway in nuclear beta-catenin accumulating cells of adamantinomatous craniopharyngiomas.
    Hölsken A; Kreutzer J; Hofmann BM; Hans V; Oppel F; Buchfelder M; Fahlbusch R; Blümcke I; Buslei R
    Brain Pathol; 2009 Jul; 19(3):357-64. PubMed ID: 18540944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Common mutations of beta-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region.
    Buslei R; Nolde M; Hofmann B; Meissner S; Eyupoglu IY; Siebzehnrübl F; Hahnen E; Kreutzer J; Fahlbusch R
    Acta Neuropathol; 2005 Jun; 109(6):589-97. PubMed ID: 15891929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of epidermal growth factor receptor during corneal epithelial migration.
    Zieske JD; Takahashi H; Hutcheon AE; Dalbone AC
    Invest Ophthalmol Vis Sci; 2000 May; 41(6):1346-55. PubMed ID: 10798649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PROP1 and CTNNB1 expression in adamantinomatous craniopharyngiomas with or without β-catenin mutations.
    Cani CM; Matushita H; Carvalho LR; Soares IC; Brito LP; Almeida MQ; Mendonça BB
    Clinics (Sao Paulo); 2011; 66(11):1849-54. PubMed ID: 22086512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.